BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32437637)

  • 21. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK
    Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Lorillon G; Jaïs X; Tcherakian C; Feuillet S; Dorfmüller P; Simonneau G; Humbert M; Tazi A
    Chest; 2012 Nov; 142(5):1150-1157. PubMed ID: 22459770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT).
    Avanesov M; Well L; Laqmani A; Derlin T; Riccardi VM; Adam G; Mautner VF; Salamon J
    Orphanet J Rare Dis; 2021 Jan; 16(1):29. PubMed ID: 33446201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pulmonary hypertension and lung transplantation].
    Kamler M; Pizanis N; Aleksic I; Ragette R; Jakob HG
    Herz; 2005 Jun; 30(4):281-5. PubMed ID: 15965804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, Type, and Molecular Spectrum of
    Pinna V; Daniele P; Calcagni G; Mariniello L; Criscione R; Giardina C; Lepri FR; Hozhabri H; Alberico A; Cavone S; Morella AT; Mandile R; Annunziata F; Di Giosaffatte N; D'Asdia MC; Versacci P; Capolino R; Strisciuglio P; Giustini S; Melis D; Digilio MC; Tartaglia M; Marino B; De Luca A
    Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31487937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.
    Savale L; Habibi A; Lionnet F; Maitre B; Cottin V; Jais X; Chaouat A; Artaud-Macari E; Canuet M; Prevot G; Chantalat-Auger C; Montani D; Sitbon O; Galacteros F; Simonneau G; Parent F; Bartolucci P; Humbert M
    Eur Respir J; 2019 Dec; 54(6):. PubMed ID: 31537700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pulmonary arterial hypertension as leading manifestation of methylmalonic aciduria: clinical characteristics and gene testing in 15 cases].
    Liu XQ; Yan H; Qiu JX; Zhang CY; Qi JG; Zhang X; Xiao HJ; Yang YL; Chen YH; Du JB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):768-777. PubMed ID: 29045954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
    Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary hypertension: a fatal complication of neurofibromatosis type 1.
    Gumbiene L; Petrulioniene Z; Rucinskas K; Maneikiene V; Serpytis P; Dranenkiene A; Laucevicius A
    Respir Care; 2011 Nov; 56(11):1844-8. PubMed ID: 21605478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
    Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
    Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance.
    Awerbach JD; Stackhouse KA; Lee J; Dahhan T; Parikh KS; Krasuski RA
    Respir Med; 2019 Apr; 150():126-130. PubMed ID: 30961938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and hemodynamic characteristics of pulmonary hypertension associated with interstitial lung disease in China.
    Wang L; Zhao QH; Pudasaini B; Jiang R; Gong SG; He J; Yuan P; Liu JM
    Clin Respir J; 2018 Mar; 12(3):915-921. PubMed ID: 28026153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Portopulmonary hypertension: survival and prognostic factors.
    Le Pavec J; Souza R; Herve P; Lebrec D; Savale L; Tcherakian C; Jaïs X; Yaïci A; Humbert M; Simonneau G; Sitbon O
    Am J Respir Crit Care Med; 2008 Sep; 178(6):637-43. PubMed ID: 18617641
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary hypertension in chronic lung diseases.
    Seeger W; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs S; Martinez FJ; Semigran MJ; Simonneau G; Wells AU; Vachiéry JL
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D109-16. PubMed ID: 24355635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement.
    Alves Júnior SF; Zanetti G; Alves de Melo AS; Souza AS; Souza LS; de Souza Portes Meirelles G; Irion KL; Hochhegger B; Marchiori E
    Respir Med; 2019 Mar; 149():9-15. PubMed ID: 30885426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.
    Naeije R; Gerges M; Vachiery JL; Caravita S; Gerges C; Lang IM
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience.
    Santoro C; Di Rocco F; Kossorotoff M; Zerah M; Boddaert N; Calmon R; Vidaud D; Cirillo M; Cinalli G; Mirone G; Giugliano T; Piluso G; D'Amico A; Capra V; Pavanello M; Cama A; Nobili B; Lyonnet S; Perrotta S
    Am J Med Genet A; 2017 Jun; 173(6):1521-1530. PubMed ID: 28422438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balloon atrial septostomy in pulmonary arterial hypertension: effect on survival and associated outcomes.
    Chiu JS; Zuckerman WA; Turner ME; Richmond ME; Kerstein D; Krishnan U; Torres A; Vincent JA; Rosenzweig EB
    J Heart Lung Transplant; 2015 Mar; 34(3):376-80. PubMed ID: 25813766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.